Sign in Subscribe
Class action lawsuits

Pomerantz LLP Announces Class Action Lawsuit Against Reckitt Benckiser Group Plc

Strategic Insights

— 1 min read

Pomerantz LLP, a renowned law firm specializing in corporate and securities litigation, has announced the filing of a class action lawsuit against Reckitt Benckiser Group Plc (RBC) on behalf of investors who purchased or acquired RBC securities during a specified period. The lawsuit concerns allegations of securities fraud and unlawful business practices by RBC and its officers and/or directors.

Key Takeaways:

  • The class action concerns whether RBC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The lawsuit is related to a $60 million verdict in a lawsuit against Reckitt's Mead Johnson subsidiary, which was found negligent in failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants.
  • A Missouri jury awarded $495 million in a similar lawsuit against Abbott Laboratories, Inc. (Abbott), making similar findings regarding Abbott's specialized baby formula and the risk of NEC.
  • Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has a reputation for fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.
  • Attorney Danielle Peyton is handling the case, and investors who inquire are advised to include their mailing address, telephone number, and the number of shares purchased.

Statistics:

  • $60 million: the verdict returned by an Illinois jury against Reckitt's Mead Johnson subsidiary in a lawsuit.
  • $495 million: the verdict returned by a Missouri jury against Abbott Laboratories, Inc. in a similar lawsuit.
  • 14%: the decline in Reckitt's American Depositary Share (ADS) price following a $60 million verdict in a lawsuit against Reckitt's Mead Johnson subsidiary.
  • 9%: the decline in Reckitt's ADS price following a $495 million verdict in a lawsuit against Abbott Laboratories, Inc.

Sources:

  • Globe Newswire (July 14, 2025)
  • Pomerantz LLP ( )
  • Chicago Tribune (March 15, 2024)

Read more